Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLBR001 and ABBV-461 in Locally Advanced or Metastatic Breast Cancer
NCT06878248Phase 1Terminated
- Sponsor
- Calibr-Skaggs Institute for Innovative Medicines
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLBR001 and ABBV-461 in breast cancer, sponsored by Calibr-Skaggs Institute for Innovative Medicines. Primary endpoints: Number of subjects with adverse events as assessed by CTCAE v5.0 and ASTCT consensus grading criteria for CRS and ICANS at 1 year, Number of subjects with replication competent lentivirus at 1 year and 1 more. Started Apr 2025; status: terminated.
02
Drugs
CLBR001ABBV-461
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06878248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878248.